Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Vishwas Seshadri M.B.A., Ph.D. | President, CEO & Director | 1.43M | -- | 1976 |
| Mr. Joseph Walter Vazzano CPA | Chief Financial Officer | 885.95k | -- | 1984 |
| Dr. Brendan M. O'Malley J.D., Ph.D. | Chief Legal Officer | 772.51k | -- | 1970 |
| Mr. Brian Kevany Ph.D. | Senior VP, CTO & CSO | -- | -- | -- |
| Mr. Gregory Gin | Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
| Ms. Alison Hardgrove | Chief People Officer | -- | -- | -- |
| Mr. Jon Voss | VP & Head of Quality | -- | -- | 1960 |
| Dr. Madhav Vasanthavada M.B.A., Ph.D. | Senior VP, Chief Commercial Officer & Head of Business Development | -- | -- | -- |
| Mr. Carl Denny | Senior Vice President of Regulatory Affairs | -- | -- | -- |
Abeona Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 84
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Corporate Governance
Upcoming Events
March 17, 2025 at 12:30 PM UTC - March 21, 2025 at 12:30 PM UTC
Abeona Therapeutics Inc. Earnings Date
Recent Events
Recent Events Information Not Available